Evaluating PET/CT Imaging for Gastric Cancer Treatment Assessment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the effectiveness of 18F-FDG and 68Ga-FAPI PET/CT imaging in assessing the outcomes of conversion therapy in patients with gastric cancer that has spread to the peritoneum. Participants will undergo a series of PET/CT scans before and after conversion therapy to monitor disease progression and treatment efficacy. The study aims to collect detailed patient data, including demographics and clinical history, to better understand the prognostic value of these imaging techniques in this specific cancer population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
3. Patients voluntarily enrolled in this study by signing an informed consent form
4. Age ≥ 18 years
5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
6. Expected life expectancy ≥ 3 months
7. Adequate organ and bone marrow function
8. Willingness to adhere to the study protocol and follow-up programme

Exclusion Criteria:

1. Signs of distant metastases other than peritoneal metastases at enrolment
2. Pregnant or breastfeeding women.
3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease

Where it's running

• Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiajia Hu
• Email: jiajiahu@shsmu.edu.cn
• Phone: 0086-13524945287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radical Surgery vs Non-Surgery in Gastric Cancer with Peritoneal Metastasis after Successful Conversion Therapy

  This study checks whether removing the stomach and nearby lymph nodes helps people with gastric cancer that has spread to the peritoneum after successful conversion therapy.

  Recruiting Phase 3 Shanghai Cancer Hospital, China · Beijing, Beijing Municipality and 30 other locations · NCT07789184

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.